Cutaneous small-vessel vasculitis with predominant IgM or IgG immune deposits on direct immunofluorescence: What does it mean in clinical practice and how does it fit within the dermatologic addendum to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides? A retrospective review of 14 patients at Mayo Clinic Authors: Kathleen M Fletcher, Julia S Lehman, David A Wetter Published: 2026 ABSTRACT Cutaneous IgM/IgG immune complex vasculitis is a newly recognized provisional subtype of single-organ vasculitis that is clinically indistinguishable from IgA vasculitis. This retrospective case series evaluated the presence, clinicopathologic characteristics and outcomes of patients with IgM and/or IgG dominance or codominance on direct immunofluorescence testing (2010–23). Cutaneous IgM/IgG immune complex vasculitis is a single-organ cutaneous small-vessel vasculitis that presents clinically with palpable purpura with a predilection for dependent areas of the body and accompanying direct immunofluorescence (DIF) microscopy revealing prominent superficial perivascular deposition of IgM and/or IgG. Cutaneous IgM/IgG immune complex vasculitis is a single-organ cutaneous small-vessel vasculitis that presents clinically with palpable purpura with a predilection for dependent areas of the body and accompanying direct immunofluorescence (DIF) microscopy revealing prominent superficial perivascular deposition of IgM and/or IgG. This is a provisional category of cutaneous vasculitis. This is a provisional category of cutaneous vasculitis. This study serves as the second study to date to provide further data about the proposed provisional category of cutaneous IgM/IgG immune complex vasculitis as a distinct subtype of single-organ cutaneous small-vessel vasculitis. This study serves as the second study to date to provide further data about the proposed provisional category of cutaneous IgM/IgG immune complex vasculitis as a distinct subtype of single-organ cutaneous small-vessel vasculitis. It emphasizes the importance of patients with cutaneous small-vessel vasculitis and IgM and/or IgG dominance and/or co­dominance on DIF undergoing a thorough work-up that includes testing for antineutrophil cytoplasmic antibody-­associated ­vasculitis, cryoglobulinaemia and autoimmune connective tissue disease, as well as a thorough review of prescription and over-the-counter medications and a focused review of systems (and testing, if indicated) for underlying infection before a diagnosis of cutaneous IgM/IgG vasculitis can be made. It emphasizes the importance of patients with cutaneous small-vessel vasculitis and IgM and/or IgG dominance and/or co­dominance on DIF undergoing a thorough work-up that includes testing for antineutrophil cytoplasmic antibody-­associated ­vasculitis, cryoglobulinaemia and autoimmune connective tissue disease, as well as a thorough review of prescription and over-the-counter medications and a focused review of systems (and testing, if indicated) for underlying infection before a diagnosis of cutaneous IgM/IgG vasculitis can be made. Clinicians have recently defined a subset of cutaneous small-­vessel vasculitis that, from a cutaneous perspective, appears clinically indistinguishable from skin-limited IgA vasculitis. However, direct immunofluorescence (DIF) reveals IgM and/or IgG dominant or codominant perivascular immune deposition without evidence of accompanying IgA deposition.1,2 This provisional cat­egory of cutaneous vasculitis has been termed ‘­cutaneous IgM/IgG immune complex vasculitis’ and was not initially included in the 2012 International Chapel Hill Consensus Conference Nomen­clature of Vasculitides.1,2 This retrospective review serves to evaluate the presence, clinicopathological characteristics and outcomes of 14 patients with cutaneous ­small-vessel vasculitis with IgM and/or IgG deposition on DIF who do not otherwise belong in one of the other defined categories of cutaneous vasculitis ­diagnosed from January 2010 through September 2023 at Mayo Clinic. Patients and methods As Mayo Clinic uses standardized DIF templates, a natural language search of DIF reports (January 2010 through September 2023) was conducted to identify reports containing at least one of the following: ‘IgG: Granular deposition within’; ‘IgG: Perivascular’; ‘IgG4: Granular deposition within’; ‘IgG4: Perivascular’; ‘IgM: Granular deposition within’; or ‘IgM: Perivascular’. Inclusion criteria were palpable purpura with predilection for dependent areas of the body, skin biopsy demonstrating leucocytoclastic vasculitis, and DIF demonstrating IgM and/or IgG dominant or codominant perivascular immune deposits. Cases were excluded if ­leucocytoclastic vasculitis was not identified on histopathology, if IgA was present on DIF or if the final clinical diagnosis was not consistent with cutaneous vasculitis. We identified 293 patients, 77 of whome had accompanying electronic health records at Mayo Clinic for review. Of the 77 reviewed patients, 14 were identified as having cutaneous small-vessel vasculitis with IgM and/or IgG dominant or codominant perivascular deposition on DIF, without IgA perivascular deposition. Cases were divided into five subgroups, including idiopathic, vasculitis associated with underlying autoimmune connective tissue disease, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, cryoglobulinaemic vasculitis and vasculitis associated with a probable aetiology (e.g. drug-induced, infection or malignancy-associated) (Figure 1). Methodology of the retrospective review. Flowchart depicting the methodology of retrospective review and identification of our cohort of 14 patients with cutaneous small-vessel vasculitis with predominant IgM and/or IgG perivascular immune deposition on direct immunofluorescence (DIF) microscopy. ANCA, antineutrophil cytoplasmic antibody; H&E, haematoxylin and eosin. Results Of the 14 cases identified, 5 (36%) were found to be idiopathic in nature and were retrospectively diagnosed as cutaneous IgM/IgG immune complex vasculitis. Two (14%) were associated with an underlying autoimmune connective tissue disorder, 1 (7%) was diagnosed as ANCA-associated vasculitis, 1 (7%) was associated with cryoglobulinaemia and 5 (36%) were associated with a probable aetiology (Figure 1). Patients with associated autoimmune connective tissue disease and underlying probable aetiologies more commonly presented with more severe cutaneous disease than patients with idiopathic disease at the time of diagnosis, as evidenced by necrotic-ulcerative lesions occurring in both patients (100%) with underlying connective tissue disease and one patient (20%) associated with a probable aetiology, and haemorrhagic bullae occurring in one (20%) patient associated with a probable aetiology. Regarding systemic symptoms, two (40%) patients with idiopathic cases had associated myalgias and arthralgias, and the patient with ANCA-associated vasculitis presented with pulmonary symptoms and was diagnosed with eosinophilic granulomatosis with polyangiitis. Details regarding demographics, clinical presentation and histopathological findings are outlined in Table 1. Table 1Demographic characteristics, clinical presentation and histopathological findings of 14 patients with cutaneous leucocytoclastic vasculitis with IgM and/or IgG dominant or codominant perivascular deposition on direct immunofluorescenceIdiopathic cutaneous IgM/IgG vasculitis (n = 5)Connective tissue disease associated (n = 2)ANCA associated (n = 1)Cryoglobulin associated (n = 1)Other probable aetiology (n = 5)Sex Female3 (60)2 (100)1 (100)0 (0)2 (40) Male2 (40)0 (0)0 (0)1 (100)3 (60)Age at diagnosis (years), median (range)66 (24–82)56 (46–69)68 (NA)62 (NA)53 (33–76)Clinical aspect of the lesions Palpable purpura5 (100)2 (100)1 (100)1 (100)5 (100) Necrotic-ulcerative lesions0 (0)2 (100)0 (0)0 (0)1 (20) Haemorrhagic bullae0 (0)0 (0)0 (0)0 (0)1 (20) Urticaria-like lesions1 (20)0 (0)0 (0)0 (0)0 (0)Sites involved Lower legs alone3 (60)2 (100)1 (100)1 (100)2 (40) Lower legs and thighs2 (40)0 (0)0 (0)0 (0)2 (40) Upper and lower extremities0 (0)0 (0)0 (0)0 (0)1 (20)Leucocytoclastic vasculitis on H&E5 (100)2 (100)1 (100)1 (100)5 (100)DIF findings IgM5 (100)2 (100)1 (100)1 (100)5 (100) IgG0 (0)0 (0)0 (0)0 (0)0 (0) IgG40 (0)0 (0)0 (0)0 (0)1 (20) IgA0 (0)0 (0)0 (0)0 (0)0 (0) C35 (100)2 (100)1 (100)1 (100)4 (80) Fibrinogen3 (60)2 (100)1 (100)1 (100)4 (80)Systemic involvement Musculoskeletal2 (40)0 (0)0 (0)0 (0)0 (0) Pulmonary0 (0)0 (0)1 (100)0 (0)0 (0) Kidney0 (0)0 (0)0 (0)0 (0)0 (0)Data are presented as n (%) unless otherwise stated. ANCA, antineutrophil cytoplasmic antibody; DIF, direct immunofluorescence; H&E, haematoxylin and eosin; NA, not applicable. Demographic characteristics, clinical presentation and histopathological findings of 14 patients with cutaneous leucocytoclastic vasculitis with IgM and/or IgG dominant or codominant perivascular deposition on direct immunofluorescence Data are presented as n (%) unless otherwise stated. ANCA, antineutrophil cytoplasmic antibody; DIF, direct immunofluorescence; H&E, haematoxylin and eosin; NA, not applicable. Among the patients in the idiopathic subgroup, laboratory data collected at the time of presentation were retrospectively reviewed to rule out any potential aetiology inducing the cutaneous vasculitis. Available data included complete blood count, a comprehensive metabolic panel, a monoclonal gammopathy screen, antinuclear antibodies, extractable nuclear antigens, complement levels, rheumatoid factor, anti-cyclic citrullinated peptide antibodies, ANCA, serum inflammatory markers, urinalysis, urine microscopy, cryoglobulins, cryofibrinogens, cold agglutinins, peripheral blood smear, recent chest imaging, hepatitis panel, HIV, group A streptococcus swab and serology, as well as a history of recent infection, medication changes or vaccine administration.3–7 No trigger was identified in any of the cases of cutaneous IgM/IgG immune complex vasculitis. In all five cases of idiopathic cutaneous small-vessel IgM/IgG immune complex vasculitis, palpable purpura was limited to the lower extremities (Figure 2), with accompanying DIF revealing superficial perivascular deposition of IgM, C3 and intermittent fibrinogen (Figure 3). No patients demonstrated IgG or IgG4 perivascular deposition. Four (80%) patients were managed with observation, topical corticosteroids alone, oral corticosteroids alone, or a combination of topical and oral corticosteroids, and subsequently experienced complete resolution without recurrence (Table 2). Representative clinical images. Cutaneous IgM/IgG immune complex vasculitis demonstrating palpable purpura with a predilection for the dependent areas of the body. (a) Brisk perivascular neutrophilic inflammation with karyorrhexis, haemorrhage and leucocytoclasis (haematoxylin and eosin stain; ×13 digital magnification). (b) Abundant granular deposition of IgM around superficial dermal capillaries (IgM; ×20 original magnification). Table 2Treatment and recurrence rates for five patients with cutaneous small-vessel IgM/IgG immune complex vasculitisTreatment and recurrenceIdiopathic cutaneous IgM/IgG vasculitisTreatment Observation1 (20) Topical corticosteroids2 (40) Oral corticosteroid taper2 (40)a Hydroxychloroquine1 (20)Recurrences 04 (80) 10 (0) 21 (20)bData are presented as n (%). aOne patient received topical and oral corticosteroids. bThe patient who experienced two recurrences of disease activity presented with predominantly palpable purpura, but due to limited urticaria-like lesions, myalgias and arthralgias, hydroxychloroquine was initiated for treatment. Treatment and recurrence rates for five patients with cutaneous small-vessel IgM/IgG immune complex vasculitis Data are presented as n (%). aOne patient received topical and oral corticosteroids. bThe patient who experienced two recurrences of disease activity presented with predominantly palpable purpura, but due to limited urticaria-like lesions, myalgias and arthralgias, hydroxychloroquine was initiated for treatment. Discussion This study provides further data about the provisional category of cutaneous IgM/IgG immune complex vasculitis as a distinct subtype of single-organ, cutaneous small-vessel vasculitis affecting primarily postcapillary venules in the skin, as previously proposed.1,2 To our knowledge, this report describes only the second study to date to characterize this unique population.2 In this study, all five patients with idiopathic cutaneous IgM/IgG immune complex vasculitis presented with palpable purpura limited to the lower extremities with accompanying DIF revealing predominance of perivascular IgM deposition. Interestingly, early analysis of this provisional entity by Marzano et al.2 also revealed a marked IgM predominance (39/41 patients showed IgM alone, 2 showed IgM and IgG codominance, and none showed IgG alone). None of the patients in this cohort demonstrated IgG or IgG4 perivascular deposition. Further studies are needed to determine whether the presence of IgG has clinical implications and whether the proposed terminology is appropriate for this provisional entity. Clinically, more severe disease at presentation was observed in cases associated with either underlying connective tissue disease or a probable aetiology, but not in idiopathic cases. This finding suggests that patients presenting with more severe disease at the time of diagnosis should be thoroughly evaluated for potential underlying causes. Regarding treatment and long-term outcomes, our findings were similar to those of the prior report of this entity,2 which also revealed mainly single-episode cases without systemic involvement and treatment predominantly with topical and oral corticosteroids that resulted in complete resolution. The similarities further suggest that this entity is a single-organ vasculitis affecting primarily the skin. Additionally, nine patients (64%) with cutaneous small-vessel vasculitis with IgM and/or IgG dominant or codominant deposition on DIF were found to have an underlying autoimmune connective tissue disease, cryoglobulinaemia, ANCA-associated vasculitis, infection or a drug-related cause (Figure 1). Therefore, it is imperative that these patients undergo a thorough investigation that includes testing for these entities, performing a thorough review of prescription and over-the-counter medications, and evaluating for potential underlying infection. Limitations of this study include a retrospective design with a small cohort size, which may have underpowered it to assess IgG perivascular deposition, a rare finding.8 This probably underestimated the prevalence of this entity due to the inability to access many electronic health records, as a large number of external DIF cases are sent to Mayo Clinic for analysis without accompanying clinic visits for evaluation. Additionally, it is likely that not all patients who clinically presented with leucocytoclastic vasculitis had a biopsy specimen sent for DIF, and the timing and location of the skin biopsy could not be standardized because of the study’s retrospective design, leading to potential sampling error and underdetection of immune deposits. Lastly, due to the retrospective study design, data collection was inconsistent, owing to the absence of a standardized protocol for ordering laboratory tests during clinical evaluations. Future studies with larger sample sizes are needed to further characterize this provisional entity. This study examined the provisional entity of cutaneous IgM/IgG immune complex vasculitis, with the conclusion that certain DIF findings may prompt additional evaluation, which must be completed before a diagnosis of idiopathic cutaneous IgM/IgG vasculitis can be assigned. Further studies are needed to evaluate the presence, clinical presentation, association with systemic disease and long-term outcomes of this provisional subset of cutaneous vasculitis, as well as to draw comparisons with IgA vasculitis and DIF-negative vasculitis. Acknowledgements The Scientific Publications staff at Mayo Clinic provided editorial consultation, proofreading, and administrative and clerical support. Contributor Information Kathleen M Fletcher, Department of Dermatology, Mayo Clinic School of Graduate Medical Education, Mayo Clinic College of Medicine and Science, Rochester, MN, USA. Julia S Lehman, Department of Dermatology (Lehman and Wetter), Mayo Clinic, Rochester, MN, USA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. David A Wetter, Department of Dermatology (Lehman and Wetter), Mayo Clinic, Rochester, MN, USA. Author contributions Kathleen M Fletcher (Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Validation, Visualization, Writing—original draft, Writing—review & editing [equal]), Julia S Lehman (Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Validation, Visualization, Writing—original draft, Writing—review & editing [equal]), and David A Wetter (Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Validation, Visualization, Writing—original draft, Writing—review & editing [equal]) Funding sources This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. Conflicts of interest The authors declare no conflicts of interest. Data availability The data underlying this article will be shared on reasonable request to the corresponding author. Ethics statement This study was approved by the Mayo Clinic Institutional Review Board (protocol 23-009651). Only patients who authorized use of their health records for research were potentially eligible for this study. Patient consent Written patient consent for publication was obtained. References Associated Data Data Availability Statement The data underlying this article will be shared on reasonable request to the corresponding author.